A number of other research analysts also recently commented on OMCL. BidaskClub raised shares of Omnicell from a hold rating to a buy rating in a research report on Thursday, November 21st. Dougherty & Co upped their price objective on shares of Omnicell from $90.00 to $92.00 and gave the company a buy rating in a research note on Thursday, November 21st. Sidoti set a $82.00 target price on shares of Omnicell and gave the stock a hold rating in a research report on Friday, October 25th. Finally, TheStreet raised shares of Omnicell from a c+ rating to a b rating in a research note on Thursday, October 24th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Omnicell has an average rating of Buy and an average target price of $83.00.
Omnicell stock traded up $1.16 during mid-day trading on Tuesday, hitting $81.52. The company’s stock had a trading volume of 193,794 shares, compared to its average volume of 326,586. Omnicell has a 52-week low of $56.96 and a 52-week high of $92.59. The company has a market cap of $3.37 billion, a PE ratio of 53.28, a price-to-earnings-growth ratio of 3.06 and a beta of 1.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.09 and a quick ratio of 1.63. The firm’s 50 day moving average is $75.61 and its 200 day moving average is $76.04.
In other Omnicell news, EVP Scott Peter Seidelmann sold 1,534 shares of Omnicell stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $75.26, for a total value of $115,448.84. Following the completion of the sale, the executive vice president now directly owns 26,333 shares in the company, valued at $1,981,821.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Randall A. Lipps sold 25,926 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $78.03, for a total transaction of $2,023,005.78. Following the completion of the sale, the chief executive officer now directly owns 128,487 shares of the company’s stock, valued at $10,025,840.61. The disclosure for this sale can be found here. Insiders have sold a total of 67,753 shares of company stock valued at $5,296,632 over the last ninety days. Company insiders own 2.77% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its holdings in Omnicell by 79.8% in the second quarter. Invesco Ltd. now owns 779,632 shares of the company’s stock worth $67,072,000 after purchasing an additional 346,029 shares in the last quarter. BlackRock Inc. raised its stake in shares of Omnicell by 5.7% in the 2nd quarter. BlackRock Inc. now owns 6,413,649 shares of the company’s stock valued at $551,764,000 after acquiring an additional 344,744 shares in the last quarter. Nuveen Asset Management LLC raised its stake in shares of Omnicell by 1,731.7% in the 2nd quarter. Nuveen Asset Management LLC now owns 348,324 shares of the company’s stock valued at $29,966,000 after acquiring an additional 329,308 shares in the last quarter. Peregrine Capital Management LLC raised its stake in shares of Omnicell by 9,014.6% in the 3rd quarter. Peregrine Capital Management LLC now owns 270,704 shares of the company’s stock valued at $19,564,000 after acquiring an additional 267,734 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Omnicell by 4.6% in the 2nd quarter. Vanguard Group Inc. now owns 4,223,552 shares of the company’s stock worth $363,352,000 after purchasing an additional 186,781 shares during the last quarter. Institutional investors and hedge funds own 98.44% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: How to Invest in Marijuana Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.